New attack on breast cancer brain spread: radiation plus two drugs
NCT ID NCT06238921
Summary
This study is testing whether adding a targeted drug (sacituzumab govitecan) and an immunotherapy drug (zimberelimab) to precise brain radiation works better and is safe for people with triple negative breast cancer that has spread to the brain. It will involve about 31 participants. The goal is to see if this three-part combination can better control cancer growth in the brain and body compared to using the targeted drug alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.